BioRestorative Therapies (BRTX) Assets Average (2011 - 2025)
BioRestorative Therapies' (BRTX) quarterly Assets Average came in at $4.9 million in Q4 2025, down 63.79% YoY from $13.4 million in Q4 2024, and down 31.34% on a QoQ basis from $7.1 million in Q3 2025.
BioRestorative Therapies (BRTX) Assets Average (2011 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 15 years of Assets Average data on file, last reported at $4.9 million in Q4 2025.
- Quarterly Assets Average fell 63.79% year-over-year to $4.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.9 million (down 63.79% YoY) and the FY2025 annual result came in at $8.2 million, down 34.28% from the prior year.
- Assets Average eased to $4.9 million in Q4 2025, from $7.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $21.7 million in Q1 2022 to a low of $2.5 million in Q3 2021.
- A 5-year average of $12.5 million and a median of $13.5 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average surged 638.39% — and 2025, when it plunged 63.79%.
- Tracing BRTX's Assets Average over 5 years: stood at $12.3 million in 2021, then surged by 39.49% to $17.2 million in 2022, then retreated by 23.12% to $13.2 million in 2023, then climbed by 1.67% to $13.4 million in 2024, then sank by 63.79% to $4.9 million in 2025.
- The last three Assets Average figures came in at $4.9 million (Q4 2025), $7.1 million (Q3 2025), and $9.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 4.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.86 Mn |
| Sep 30, 2025 | 7.08 Mn |
| Jun 30, 2025 | 9.42 Mn |
| Mar 31, 2025 | 11.30 Mn |
| Dec 31, 2024 | 13.43 Mn |
| Sep 30, 2024 | 15.35 Mn |
| Jun 30, 2024 | 17.04 Mn |
| Mar 31, 2024 | 15.28 Mn |
| Dec 31, 2023 | 13.21 Mn |
| Sep 30, 2023 | 13.55 Mn |
| Jun 30, 2023 | 13.69 Mn |
| Mar 31, 2023 | 15.26 Mn |
| Dec 31, 2022 | 17.18 Mn |
| Sep 30, 2022 | 18.68 Mn |
| Jun 30, 2022 | 20.18 Mn |
| Mar 31, 2022 | 21.69 Mn |
| Dec 31, 2021 | 12.31 Mn |
| Sep 30, 2021 | 2.53 Mn |
| Jun 30, 2021 | 3.29 Mn |
| Mar 31, 2021 | 4.02 Mn |